| High performance plasma amyloid-β biomarkers for Alzheimer’s disease A Nakamura, N Kaneko, VL Villemagne, T Kato, J Doecke, V Doré, ... Nature 554 (7691), 249-254, 2018 | 1694 | 2018 |
| Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions VL Villemagne, V Doré, SC Burnham, CL Masters, CC Rowe Nature Reviews Neurology 14 (4), 225-236, 2018 | 464 | 2018 |
| Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline R Ossenkoppele, A Pichet Binette, C Groot, R Smith, O Strandberg, ... Nature medicine 28 (11), 2381-2387, 2022 | 262 | 2022 |
| Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a … SC Burnham, P Bourgeat, V Doré, G Savage, B Brown, S Laws, P Maruff, ... The Lancet Neurology 15 (10), 1044-1053, 2016 | 234 | 2016 |
| Multisite study of the relationships between antemortem [11C] PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology R La Joie, N Ayakta, WW Seeley, E Borys, AL Boxer, C DeCarli, V Doré, ... Alzheimer's & Dementia 15 (2), 205-216, 2019 | 225 | 2019 |
| Sex, amyloid, and APOE ε4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts RF Buckley, EC Mormino, RE Amariglio, MJ Properzi, JS Rabin, YY Lim, ... Alzheimer's & Dementia 14 (9), 1193-1203, 2018 | 223 | 2018 |
| Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease V Doré, VL Villemagne, P Bourgeat, J Fripp, O Acosta, G Chetélat, L Zhou, ... JAMA neurology 70 (7), 2013 | 221 | 2013 |
| In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease VL Villemagne, S Furumoto, MT Fodero-Tavoletti, RS Mulligan, J Hodges, ... European journal of nuclear medicine and molecular imaging 41, 816-826, 2014 | 216 | 2014 |
| Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease P Chatterjee, S Pedrini, NJ Ashton, M Tegg, K Goozee, AK Singh, ... Alzheimer's & Dementia 18 (6), 1141-1154, 2022 | 164 | 2022 |
| Aβ-amyloid and tau imaging in dementia VL Villemagne, V Dore, P Bourgeat, SC Burnham, S Laws, O Salvado, ... Seminars in nuclear medicine 47 (1), 75-88, 2017 | 161 | 2017 |
| Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: a cross‐sectional and longitudinal study in the AIBL cohort P Chatterjee, S Pedrini, JD Doecke, R Thota, VL Villemagne, V Doré, ... Alzheimer's & Dementia 19 (4), 1117-1134, 2023 | 137 | 2023 |
| Comparison of MR-less PiB SUVR quantification methods P Bourgeat, VL Villemagne, V Dore, B Brown, SL Macaulay, R Martins, ... Neurobiology of aging 36, S159-S166, 2015 | 137 | 2015 |
| Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL P Bourgeat, V Doré, J Fripp, D Ames, CL Masters, O Salvado, ... Neuroimage 183, 387-393, 2018 | 127 | 2018 |
| 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids CC Rowe, V Doré, G Jones, D Baxendale, RS Mulligan, S Bullich, ... European journal of nuclear medicine and molecular imaging 44, 2053-2059, 2017 | 127 | 2017 |
| Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease S Amadoru, V Doré, CA McLean, F Hinton, CE Shepherd, GM Halliday, ... Alzheimer's research & therapy 12 (1), 22, 2020 | 122 | 2020 |
| Standardized expression of 18F-NAV4694 and 11C-PiB β-amyloid PET results with the Centiloid scale CC Rowe, G Jones, V Doré, S Pejoska, L Margison, RS Mulligan, ... Journal of Nuclear Medicine 57 (8), 1233-1237, 2016 | 116 | 2016 |
| Fifteen years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality … C Fowler, SR Rainey-Smith, S Bird, J Bomke, P Bourgeat, BM Brown, ... Journal of Alzheimer's disease reports 5 (1), 443-468, 2021 | 115 | 2021 |
| Insulin resistance is associated with reductions in specific cognitive domains and increases in CSF tau in cognitively normal adults SM Laws, S Gaskin, A Woodfield, V Srikanth, D Bruce, PE Fraser, T Porter, ... Scientific reports 7 (1), 9766, 2017 | 91 | 2017 |
| Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods MR Battle, LC Pillay, VJ Lowe, D Knopman, B Kemp, CC Rowe, V Doré, ... EJNMMI research 8, 1-11, 2018 | 83 | 2018 |
| Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer’s disease G Chételat, R Ossenkoppele, VL Villemagne, A Perrotin, B Landeau, ... Brain 139 (9), 2528-2539, 2016 | 83 | 2016 |
Christopher Cleon RoweUniversity of Melbourneaustin.org.au üzerinde doğrulanmış e-posta adresine sahip